Bcr-Abl tyrosine-kinase inhibitor

Bcr-Abl tyrosine-kinase inhibitor

Playing 1/13
  • ABL001 – a new BCR-ABL inhibitor for chronic myeloid leukemia (CML) treatment

    YouTube 01:12
  • Defining Suboptimal Response to BCR-ABL TKI Therapy in CML

    YouTube 03:31
  • Gleevecs mechanism of Action

    YouTube 02:27
  • Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia

    YouTube 03:12
  • Managing BCR-ABL Inhibitor Associated Skin Rash

    YouTube 01:40
  • Amino Acid Metabolism: Introduction – Biochemistry | Lecturio

    YouTube 02:43
  • Oxygen - Periodic Table of Videos

    YouTube 06:18
  • Chlorine - Periodic Table of Videos

    YouTube 08:41

    YouTube 12:30
  • ATP & Respiration: Crash Course Biology #7

    YouTube 13:26
  • Hydrogen Bonds - What Are Hydrogen Bonds - How Do Hydrogen Bonds Form

    YouTube 02:48
  • Nucleotide vs Nucleoside |Fast Differences and Comparison|

    YouTube 02:38
  • Gene | Metamorphosis | Grand Beatbox Battle Wildcard 2021

    YouTube 02:23

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality was discovered by Peter Nowell in 1960 and is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.

Discover in context

This site is not available in the landscape mode.
Please rotate your phone or install our app.